Re:The Fed's Big Problem, There Are Two Economies but Only O...
by JamesBarney on Tuesday March 19, 2024 @02:39AM
(#39753453)
> Okay, they also have side effects, and it is possible the disease burden caused by the side effects may (in the long-run) turn out to be worse than the disease burden they prevent. But, while that's a possibility, it is only a possibility, a possibility which could easily not come pass to
This is very unlikely to happen. This isn't like other obesity drugs that were first in class, glp-1 agonists have been around a long time and have a great safety record.
Drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are making massive profits, and also have decent odds of preventing many obesity-induced (and also diabetes-induced) diseases
Okay, they also have side effects, and it is possible the disease burden caused by the side effects may (in the long-run) turn out to be worse than the disease burden they prevent. But, while that's a possibility, it is only a possibility, a possibility which could easily not come pass to
And even if some of those drugs turn out to have unacceptable side effects in the long-run, there are other drugs in that class in the pipeline which might avoid those side effects, in which case the profits will shift to those